Evidence map›Paper›PMID 23968624›Full record

ArticleHealthcare policy = Politiques de sante2013

Money left on the table: generic drug prices in Canada.

Michael R Law

Abstract readComparative Study
In one paragraph

Article in Healthcare policy = Politiques de sante, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. When are Pharmaceuticals Priced Fairly? An Alternative Risk-Sharing Model for Pharmaceutical Pricing.Health care analysis : HCA : journal of health philosophy and policy · 2020
    Article
  2. Article
  3. Review
  4. Article
  5. Generic drugs in Canada: an examination of tiered pricing.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2015
    Article
  6. The impact of pharmaceutical innovation on premature cancer mortality in Canada, 2000-2011.International journal of health economics and management · 2015
    Article
  7. Article
  8. Article
  9. Pan-Canadian overpricing of medicines: a 6-country study of cost control for generic medicines.Open medicine : a peer-reviewed, independent, open-access journal · 2014
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Michael R LawCentre for Health Services and Policy Research, School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada. mlaw@chspr.ubc.ca

Funding

Canadian Institutes of Health Research MOP-221233
6 · The paper itself

Abstract

backgroundGeneric drugs are a major cost-saving opportunity for patients and drug plans. While almost every province has reduced generic drug prices, we have no information on whether these new prices are internationally competitive. Therefore, I compared Canadian prices to those in two other countries.

methodsI used 2009 data from the IMS Brogan Canadian CompuScript and PharmaStat databases and studied the 100 most frequently dispensed generic products in Ontario, which has Canada's lowest generic prices. I compared these prices to those in public drug programs in the United States and New Zealand that use tendering. Using these alternative prices, I calculated the potential savings in Ontario.

resultsOf the top 100 generic products, 82 were listed on an international formulary. In 90% of cases, generic products were less expensive in other countries. If Ontario had obtained the lowest comparator price for these products, the annual public sector and overall drug expenditure savings would have been $129 million and $245 million, respectively. Further, the province could have publicly paid for all these generic drugs - both public and private - and saved $87 million compared to current public sector expenditures. DISCUSSION: Even after recent reforms, generic drug prices in Canada remain high by international standards. I found that if Ontario had obtained commonly used generic drugs at international best prices, the province could have publicly paid for all generic drugs and lowered annual expenditures by nearly a quarter-billion dollars.

Indexed as

CanadaCost SavingsDrug CostsDrugs, GenericFormularies as TopicHumansNew ZealandOntarioUnited StatesDrugs, Generic

Identifiers

PMID23968624
PMCPMC3999558

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.